Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

The list includes Novo Nordisk's blockbuster diabetes injection Ozempic, weight loss shot Wegovy and diabetes pill Rybelsus, ...

A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...

President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

although there is a good chance they will recover and still deliver strong returns to patient investors. But which one is likely to perform better than the other? Let's find out. Novo Nordisk has ...

The biggest talking point in the pharmaceutical industry at the moment revolves around treatments known as glucagon-like peptide-1 (GLP-1) agonists. GLP-1 agonists are used to treat diabetes and ...

Novo Nordisk should deliver a 24% CAGR over two years, driven by robust obesity drug market growth and improved operational performance, with an intrinsic value implying a 29% safety margin.

We came across a bullish thesis on Novo Nordisk A/S (NYSE ... challenges in tolerability at the highest dose and variability in patient adherence have emerged as critical areas of focus.

Deep-pocketed investors have adopted a bullish approach towards Novo Nordisk NVO, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled ...